U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Primary Peritoneal Carcinoma

MedGen UID:
1660575
•Concept ID:
C4726621
•
Neoplastic Process
Synonym: Refractory Primary Peritoneal Cancer

Definition

Primary peritoneal carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis.
Sauerbruch T, Appenrodt B, Schmitz V, Spengler U
Dtsch Arztebl Int 2013 Feb;110(8):126-32, I. Epub 2013 Feb 22 doi: 10.3238/arztebl.2013.0126. PMID: 23505400Free PMC Article
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623

Recent clinical studies

Etiology

ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J
Future Oncol 2023 Jul;19(23):1577-1591. Epub 2023 Jun 19 doi: 10.2217/fon-2023-0246. PMID: 37334673
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
Hamontri S, Tantitamit T
Asian Pac J Cancer Prev 2023 Apr 1;24(4):1401-1405. doi: 10.31557/APJCP.2023.24.4.1401. PMID: 37116164Free PMC Article
Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C, Charakorn C, Chittithaworn S, Lertkhachonsuk AA
J Obstet Gynaecol 2022 Aug;42(6):2331-2335. Epub 2022 Apr 26 doi: 10.1080/01443615.2022.2049724. PMID: 35470751
Randomised controlled trial testing the feasibility of an exercise and nutrition intervention for patients with ovarian cancer during and after first-line chemotherapy (BENITA-study).
Maurer T, Belau MH, von Grundherr J, Schlemmer Z, Patra S, Becher H, Schulz KH, Zyriax BC, Schmalfeldt B, Chang-Claude J
BMJ Open 2022 Feb 23;12(2):e054091. doi: 10.1136/bmjopen-2021-054091. PMID: 35197344Free PMC Article
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH, Lee S, Kim HG, Lee HJ, Jung KH, Lee SC, Lee NR, Yun J, Woo IS, Park KH, Kim KH, Kim HY, Rha SY, Byun JH
Gynecol Oncol 2015 Feb;136(2):212-7. Epub 2014 Nov 22 doi: 10.1016/j.ygyno.2014.11.017. PMID: 25462205

Diagnosis

Randomised controlled trial testing the feasibility of an exercise and nutrition intervention for patients with ovarian cancer during and after first-line chemotherapy (BENITA-study).
Maurer T, Belau MH, von Grundherr J, Schlemmer Z, Patra S, Becher H, Schulz KH, Zyriax BC, Schmalfeldt B, Chang-Claude J
BMJ Open 2022 Feb 23;12(2):e054091. doi: 10.1136/bmjopen-2021-054091. PMID: 35197344Free PMC Article
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623
The sensitivity and specificity of clinical diagnostics during five decades. Toward an understanding of necessary fallibility.
Anderson RE, Hill RB, Key CR
JAMA 1989 Mar 17;261(11):1610-7. PMID: 2645451

Therapy

Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C, Charakorn C, Chittithaworn S, Lertkhachonsuk AA
J Obstet Gynaecol 2022 Aug;42(6):2331-2335. Epub 2022 Apr 26 doi: 10.1080/01443615.2022.2049724. PMID: 35470751
Randomised controlled trial testing the feasibility of an exercise and nutrition intervention for patients with ovarian cancer during and after first-line chemotherapy (BENITA-study).
Maurer T, Belau MH, von Grundherr J, Schlemmer Z, Patra S, Becher H, Schulz KH, Zyriax BC, Schmalfeldt B, Chang-Claude J
BMJ Open 2022 Feb 23;12(2):e054091. doi: 10.1136/bmjopen-2021-054091. PMID: 35197344Free PMC Article
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273

Prognosis

Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto.
Hashimoto D, Satoi S, Fujii T, Sho M, He J, Hackert T, Del Chiaro M, Jang JY, Gulla A, Yoon YS, Shan YS, Lou W, Valente R, Furuse J, Oba A, Nagai M, Terai T, Tanaka H, Sakai A, Yamamoto T, Yamaki S, Matsumoto I, Murakami Y, Takaori K, Takeyama Y
Pancreatology 2023 Sep;23(6):682-688. Epub 2023 Jul 20 doi: 10.1016/j.pan.2023.07.005. PMID: 37507301
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
Hamontri S, Tantitamit T
Asian Pac J Cancer Prev 2023 Apr 1;24(4):1401-1405. doi: 10.31557/APJCP.2023.24.4.1401. PMID: 37116164Free PMC Article
Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C, Charakorn C, Chittithaworn S, Lertkhachonsuk AA
J Obstet Gynaecol 2022 Aug;42(6):2331-2335. Epub 2022 Apr 26 doi: 10.1080/01443615.2022.2049724. PMID: 35470751
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article

Clinical prediction guides

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW
Gynecol Oncol 2015 Aug;138(2):272-7. Epub 2015 May 27 doi: 10.1016/j.ygyno.2015.05.023. PMID: 26026738
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P
Gynecol Oncol 2011 Jul;122(1):116-20. Epub 2011 Apr 22 doi: 10.1016/j.ygyno.2011.03.030. PMID: 21514634Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...